NOI to Sole Source to QuVa Pharma, Inc.
Archived on May 21, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 9:00 AM EDT
- Posted
- May 1, 2026
- Notice type
- Presolicitation
- Set-aside
- No Set aside used
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH OLAO
- Place of performance
- Bethesda, Maryland, 20892
- Last updated
- Oct 30, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- NOI-OD-26-000038
- Notice ID
- 5816fd15c86b44d69534709710fa32ff
Description
The purpose of this acquisition is to purchase 503b compounded Intravenous (IV) Narcotics for patient care. Market research has been conducted with only two responses, from QUVA, the known Compounder and distributor for these IV narcotics. Through trade shows, continuous learning seminars and trade journals, the CC Pharmacy Department stays abreast of the industry and is current on the availability of singular distribution outlets for these medications.
• Product Service Code: 6515 – Medical and Surgical Instruments, Equipment, and Supplies
• NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing
• Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA
POTS: 26-000038
Description:
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH) intends to award a one-year contract to QuVa Pharma, Inc., located at 3 Sugar Creek Center Boulevard, Sugarland, TX 77478, on a firm fixed price sole source award basis for the purchase of 503b compound Intravenous (IV) Narcotics for patient care.
The proposed vendor, QuVa Pharma Inc., is the Original Manufacturer and has not designated other distributors of IV narcotics in the U.S.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to huda.malik@nih.gov by May 6, 2026 at 9 am EST.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
JOFOC QUVA 503B IV NARCOTICS 04.2026_FG.pdf
671 KBAdded in Presolicitation version 3Posted
Lifecycle
- 3Version 3PresolicitationArchivedCurrent
NOI to Sole Source to QuVa Pharma, Inc.
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
NOI-OD-26-000038
Archive Date
May 21, 2026
Office Address
BETHESDA, MD, 20892